AP2013006707A0 - 2-Quinolinyl-acetic acid derivatives as HIV antiviral compounds - Google Patents

2-Quinolinyl-acetic acid derivatives as HIV antiviral compounds

Info

Publication number
AP2013006707A0
AP2013006707A0 AP2013006707A AP2013006707A AP2013006707A0 AP 2013006707 A0 AP2013006707 A0 AP 2013006707A0 AP 2013006707 A AP2013006707 A AP 2013006707A AP 2013006707 A AP2013006707 A AP 2013006707A AP 2013006707 A0 AP2013006707 A0 AP 2013006707A0
Authority
AP
ARIPO
Prior art keywords
quinolinyl
acetic acid
acid derivatives
antiviral compounds
hiv antiviral
Prior art date
Application number
AP2013006707A
Other languages
English (en)
Inventor
Randall W Vivian
Lianhong Xu
Jianyu Sun
Original Assignee
Gilead Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44508471&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AP2013006707(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Gilead Sciences Inc filed Critical Gilead Sciences Inc
Publication of AP2013006707A0 publication Critical patent/AP2013006707A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/18—Halogen atoms or nitro radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/04—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to the ring carbon atoms
    • C07D215/06—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to the ring carbon atoms having only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D215/14—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C07D215/227—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Communicable Diseases (AREA)
  • AIDS & HIV (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Quinoline Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AP2013006707A 2010-07-02 2011-07-01 2-Quinolinyl-acetic acid derivatives as HIV antiviral compounds AP2013006707A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US36133510P 2010-07-02 2010-07-02
PCT/US2011/042881 WO2012003498A1 (en) 2010-07-02 2011-07-01 2 -quinolinyl- acetic acid derivatives as hiv antiviral compounds

Publications (1)

Publication Number Publication Date
AP2013006707A0 true AP2013006707A0 (en) 2013-02-28

Family

ID=44508471

Family Applications (1)

Application Number Title Priority Date Filing Date
AP2013006707A AP2013006707A0 (en) 2010-07-02 2011-07-01 2-Quinolinyl-acetic acid derivatives as HIV antiviral compounds

Country Status (27)

Country Link
US (1) US9296758B2 (enExample)
EP (1) EP2588455B1 (enExample)
JP (2) JP5806735B2 (enExample)
KR (1) KR20130124291A (enExample)
CN (1) CN103209963A (enExample)
AP (1) AP2013006707A0 (enExample)
AR (1) AR082080A1 (enExample)
AU (1) AU2011274323B2 (enExample)
BR (1) BR112012033689A2 (enExample)
CA (1) CA2802492C (enExample)
CL (1) CL2012003723A1 (enExample)
CO (1) CO6660514A2 (enExample)
CR (1) CR20130043A (enExample)
EA (1) EA201291301A1 (enExample)
EC (1) ECSP13012418A (enExample)
ES (1) ES2669793T3 (enExample)
MA (1) MA34400B1 (enExample)
MX (1) MX2012015293A (enExample)
NZ (1) NZ604716A (enExample)
PE (1) PE20130525A1 (enExample)
PH (1) PH12013500015A1 (enExample)
PT (1) PT2588455T (enExample)
SG (1) SG186821A1 (enExample)
TW (1) TWI458711B (enExample)
UY (1) UY33479A (enExample)
WO (1) WO2012003498A1 (enExample)
ZA (1) ZA201209602B (enExample)

Families Citing this family (161)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ593110A (en) 2008-12-09 2013-06-28 Gilead Sciences Inc pteridinone derivatives as MODULATORS OF TOLL-LIKE RECEPTORS
WO2012003498A1 (en) 2010-07-02 2012-01-05 Gilead Sciences, Inc. 2 -quinolinyl- acetic acid derivatives as hiv antiviral compounds
MA34397B1 (fr) 2010-07-02 2013-07-03 Gilead Sciences Inc Dérivés d'acide napht-2-ylacétique dans le traitement du sida
EP2511273B8 (en) * 2011-04-15 2019-06-26 Hivih Inhibitors of viral replication, their process of preparation and their therapeutical uses
WO2012145728A1 (en) 2011-04-21 2012-10-26 Gilead Sciences, Inc. Benzothiazole compounds and their pharmaceutical use
PT2729448E (pt) 2011-07-06 2015-12-02 Gilead Sciences Inc Compostos para o tratamento de vih
US8791108B2 (en) 2011-08-18 2014-07-29 Bristol-Myers Squibb Company Inhibitors of human immunodeficiency virus replication
JP6099149B2 (ja) 2011-10-25 2017-03-22 塩野義製薬株式会社 Ｈｉｖ複製阻害剤
CA2860015C (en) 2011-12-22 2020-07-07 Universite Laval Three-dimensional cavities of dendritic cell immunoreceptor (dcir), compounds binding thereto and therapeutic applications related to inhibition of human immunodeficiency virus type-1 (hiv-1)
WO2013103738A1 (en) * 2012-01-04 2013-07-11 Gilead Sciences, Inc. Napthalene acetic acid derivatives against hiv infection
WO2013103724A1 (en) * 2012-01-04 2013-07-11 Gilead Sciences, Inc. 2- (tert - butoxy) -2- (7 -methylquinolin- 6 - yl) acetic acid derivatives for treating aids
US8629276B2 (en) 2012-02-15 2014-01-14 Bristol-Myers Squibb Company Inhibitors of human immunodeficiency virus replication
US9034882B2 (en) 2012-03-05 2015-05-19 Bristol-Myers Squibb Company Inhibitors of human immunodeficiency virus replication
US9006235B2 (en) 2012-03-06 2015-04-14 Bristol-Myers Squibb Company Inhibitors of human immunodeficiency virus replication
EP3070081B1 (en) 2012-04-20 2018-02-28 Gilead Sciences, Inc. Benzothiazol-6-yl acetic acid derivatives and their use for treating an hiv infection
EP2662379A1 (en) * 2012-05-07 2013-11-13 Universiteit Antwerpen Recycling of organotin compounds
US8906929B2 (en) 2012-08-16 2014-12-09 Bristol-Myers Squibb Company Inhibitors of human immunodeficiency virus replication
EP2719685A1 (en) 2012-10-11 2014-04-16 Laboratoire Biodim Inhibitors of viral replication, their process of preparation and their therapeutical uses
DK3067358T3 (da) 2012-12-21 2019-11-04 Gilead Sciences Inc Polycykliske carbamoylpyridon-forbindelser og deres farmaceutiske anvendelse
NZ727792A (en) 2013-01-09 2018-04-27 Gilead Sciences Inc Therapeutic compounds
JP5941598B2 (ja) 2013-01-09 2016-06-29 ギリアード サイエンシーズ， インコーポレイテッド ５員ヘテロアリールおよびそれらの抗ウイルス剤としての使用
TW201443037A (zh) 2013-01-09 2014-11-16 Gilead Sciences Inc 治療用化合物
TW201441197A (zh) * 2013-01-31 2014-11-01 Shionogi & Co Ｈｉｖ複製抑制劑
TWI694071B (zh) 2013-03-01 2020-05-21 美商基利科學股份有限公司 治療反轉錄病毒科(Retroviridae)病毒感染之治療性化合物
ES2623777T3 (es) 2013-03-13 2017-07-12 VIIV Healthcare UK (No.5) Limited Inhibidores de la replicación del virus de la inmunodeficiencia humana
WO2014164467A1 (en) 2013-03-13 2014-10-09 Bristol-Myers Squibb Company Inhibitors of human immunodeficiency virus replication
WO2014164428A1 (en) 2013-03-13 2014-10-09 Bristol-Myers Squibb Company Inhibitors of human immunodeficiency virus replication
CN105189503B (zh) 2013-03-14 2017-03-22 百时美施贵宝公司 人免疫缺陷病毒复制的抑制剂
EP2970297A1 (en) 2013-03-14 2016-01-20 Bristol-Myers Squibb Company Inhibitors of human immunodeficiency virus replication
EP2821082A1 (en) 2013-07-05 2015-01-07 Laboratoire Biodim Method of producing an inactivated lentivirus, especially HIV, vaccine, kit and method of use
EP2821104A1 (en) 2013-07-05 2015-01-07 Laboratoire Biodim Inhibitors of viral replication, their process of preparation and their therapeutical uses
PL3019503T3 (pl) 2013-07-12 2018-01-31 Gilead Sciences Inc Policykliczne związki karbamoilopirydonowe i ich zastosowanie do leczenia infekcji hiv
NO2865735T3 (enExample) 2013-07-12 2018-07-21
US9944656B2 (en) 2014-02-12 2018-04-17 VIIV Healthcare UK (No.5) Limited Benzothiazole macrocycles as inhibitors of human immunodeficiency virus replication
WO2015126743A1 (en) 2014-02-18 2015-08-27 Bristol-Myers Squibb Company Pyrazolopyrimidine macrocycles as inhibitors of human immunodeficiency virus replication
US9409922B2 (en) 2014-02-18 2016-08-09 Bristol-Myers Squibb Company Imidazopyridine macrocycles as inhibitors of human immunodeficiency virus replication
EP3116879A1 (en) 2014-02-18 2017-01-18 VIIV Healthcare UK (No.5) Limited Imidazopyrimidine macrocycles as inhibitors of human immunodeficiency virus replication
US9273067B2 (en) 2014-02-19 2016-03-01 Bristol-Myers Squibb Company Pyrazolopyrimidine macrocycles as inhibitors of human immunodeficiency virus replication
PT3107913T (pt) 2014-02-19 2018-09-28 Viiv Healthcare Uk No 5 Ltd Inibidores da replicação do vírus da imunodeficiência humana
US10202353B2 (en) 2014-02-28 2019-02-12 Gilead Sciences, Inc. Therapeutic compounds
WO2015147247A1 (ja) * 2014-03-28 2015-10-01 塩野義製薬株式会社 Ｈｉｖ複製阻害作用を有する３環性誘導体
JP6579549B2 (ja) * 2014-05-16 2019-09-25 塩野義製薬株式会社 Ｈｉｖ複製阻害作用を有する３環性複素環誘導体
TW201613936A (en) 2014-06-20 2016-04-16 Gilead Sciences Inc Crystalline forms of(2R,5S,13aR)-8-hydroxy-7,9-dioxo-n-(2,4,6-trifluorobenzyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazepine-10-carboxamide
NO2717902T3 (enExample) 2014-06-20 2018-06-23
EA201790024A1 (ru) 2014-07-11 2017-07-31 Джилид Сайэнс, Инк. Модуляторы toll-подобных рецепторов для лечения вич
WO2016036759A1 (en) 2014-09-04 2016-03-10 Gilead Sciences, Inc. Methods of treating or preventing hiv in patients using a combination of tenofovir alafenamide and dolutegravir
US9738646B2 (en) 2014-09-16 2017-08-22 Gilead Sciences, Inc. Solid forms of a toll-like receptor modulator
TWI695003B (zh) 2014-12-23 2020-06-01 美商基利科學股份有限公司 多環胺甲醯基吡啶酮化合物及其醫藥用途
SG11201705192PA (en) 2014-12-24 2017-07-28 Gilead Sciences Inc Fused pyrimidine compounds for the treatment of hiv
ES2705709T3 (es) 2014-12-24 2019-03-26 Gilead Sciences Inc Compuestos de isoquinolina para el tratamiento del VIH
TWI770552B (zh) 2014-12-24 2022-07-11 美商基利科學股份有限公司 喹唑啉化合物
SG11201705069YA (en) 2014-12-26 2017-07-28 Univ Emory N4-hydroxycytidine and derivatives and anti-viral uses related thereto
AU2016216673B2 (en) 2015-03-04 2017-02-02 Gilead Sciences, Inc. Toll like receptor modulator compounds
EP3277691B1 (en) 2015-04-02 2019-01-30 Gilead Sciences, Inc. Polycyclic-carbamoylpyridone compounds and their pharmaceutical use
CA2987384A1 (en) 2015-05-29 2016-12-08 Shionogi & Co., Ltd. Nitrogen-containing tricyclic derivative having hiv replication inhibitory activity
US20210292327A1 (en) 2015-08-26 2021-09-23 Gilead Sciences, Inc. Deuterated toll-like receptor modulators
WO2017048727A1 (en) 2015-09-15 2017-03-23 Gilead Sciences, Inc. Modulators of toll-like recptors for the treatment of hiv
JP2018529714A (ja) 2015-09-30 2018-10-11 ギリアード サイエンシーズ， インコーポレイテッド Ｈｉｖの処置のための化合物および組合せ物
EA201891186A1 (ru) 2015-12-15 2018-12-28 Джилид Сайэнс, Инк. Антитела, нейтрализующие вирус иммунодефицита человека
WO2018020357A1 (en) * 2016-07-25 2018-02-01 Viiv Healthcare Uk Limited Indoline derivatives
JP6716785B2 (ja) 2016-08-19 2020-07-01 ギリアード サイエンシーズ， インコーポレイテッド Ｈｉｖウイルス感染症の予防的または治療的処置に有用な治療用化合物
WO2018042332A1 (en) 2016-08-31 2018-03-08 Glaxosmithkline Intellectual Property (No.2) Limited Combinations and uses and treatments thereof
WO2018042331A1 (en) 2016-08-31 2018-03-08 Glaxosmithkline Intellectual Property (No.2) Limited Combinations and uses and treatments thereof
AU2017318601B2 (en) 2016-09-02 2020-09-03 Gilead Sciences, Inc. Toll like receptor modulator compounds
US10640499B2 (en) 2016-09-02 2020-05-05 Gilead Sciences, Inc. Toll like receptor modulator compounds
WO2018051250A1 (en) 2016-09-14 2018-03-22 Viiv Healthcare Company Combination comprising tenofovir alafenamide, bictegravir and 3tc
ES2992772T3 (en) 2016-09-28 2024-12-18 Gilead Sciences Inc Benzothiazol-6-yl acetic acid derivatives and their use for treating hiv infection
EP3532478B1 (en) 2016-10-27 2021-05-26 Gilead Sciences, Inc. Crystalline form of darunavir free base
JP2020503352A (ja) 2017-01-03 2020-01-30 ヴィーブ ヘルスケア ユーケー（ナンバー５）リミテッド ヒト免疫不全ウイルス複製の阻害剤としてのピリジン−３−イル酢酸誘導体
EP3565809A1 (en) 2017-01-03 2019-11-13 ViiV Healthcare UK (No.5) Limited Pyridin-3-yl acetic acid derivatives as inhibitors of human immunodeficiency virus replication
TW202510891A (zh) 2017-01-31 2025-03-16 美商基利科學股份有限公司 替諾福韋埃拉酚胺(tenofovir alafenamide)之晶型
JOP20180009A1 (ar) 2017-02-06 2019-01-30 Gilead Sciences Inc مركبات مثبط فيروس hiv
CA3054826A1 (en) 2017-03-16 2018-09-20 Celgene Car Llc Mk2 inhibitors, synthesis thereof, and intermediates thereto
US11124525B2 (en) 2017-03-16 2021-09-21 Celgene Car Llc Heteroaryl compounds useful as MK2 inhibitors
US10882907B2 (en) 2017-06-21 2021-01-05 Gilead Sciences, Inc. Multispecific antibodies that target HIV GP120 and CD3
JP7287906B2 (ja) 2017-06-30 2023-06-06 ヴィーブ ヘルスケア カンパニー 組み合わせ並びにその使用及びそれによる治療
ES2892402T3 (es) 2017-08-01 2022-02-04 Gilead Sciences Inc Formas cristalinas de ((S)-((((2R,5R)-5-(6-amino-9H-purin-9-il)-4-fluoro-2,5-dihidrofuran-2-il)oxi)metil)(fenoxi)fosforil)-L-alaninato de etilo para tratar infecciones virales
TWI687415B (zh) 2017-08-17 2020-03-11 美商基利科學股份有限公司 Hiv蛋白質膜抑制劑之固體形式
AR112412A1 (es) 2017-08-17 2019-10-23 Gilead Sciences Inc Formas de sal de colina de un inhibidor de la cápside del vih
US11229638B2 (en) 2017-08-22 2022-01-25 Gilead Sciences, Inc. Therapeutic heterocyclic compounds
JOP20180092A1 (ar) 2017-10-13 2019-04-13 Gilead Sciences Inc مثبطات hiv بروتياز
EP3700573A1 (en) 2017-10-24 2020-09-02 Gilead Sciences, Inc. Methods of treating patients co-infected with a virus and tuberculosis
PL3706762T3 (pl) 2017-12-07 2025-02-10 Emory University N4-hydroksycytydyna i pochodne oraz związane z nimi zastosowania przeciwwirusowe
CN111511754B (zh) 2017-12-20 2023-09-12 捷克共和国有机化学与生物化学研究所 活化sting转接蛋白的具有膦酸酯键的2’3’环状二核苷酸
US10966999B2 (en) 2017-12-20 2021-04-06 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 3′3′ cyclic dinucleotides with phosphonate bond activating the sting adaptor protein
KR102497051B1 (ko) 2018-01-19 2023-02-09 길리애드 사이언시즈, 인코포레이티드 빅테그라비르의 대사물
ES2958828T3 (es) 2018-02-15 2024-02-15 Gilead Sciences Inc Derivados de piridina y su uso para tratar una infección por VIH
PL3752496T3 (pl) 2018-02-16 2023-11-27 Gilead Sciences, Inc. Sposoby i związki pośrednie do wytwarzania związku terapeutycznego przydatnego w leczeniu infekcji wirusowej retroviridae
TWI833744B (zh) 2018-04-06 2024-03-01 捷克科學院有機化學與生物化學研究所 3'3'-環二核苷酸
TW202005654A (zh) 2018-04-06 2020-02-01 捷克科學院有機化學與生物化學研究所 ２，２，─環二核苷酸
TWI818007B (zh) 2018-04-06 2023-10-11 捷克科學院有機化學與生物化學研究所 2'3'-環二核苷酸
US20190359645A1 (en) 2018-05-03 2019-11-28 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 2'3'-cyclic dinucleotides comprising carbocyclic nucleotide
PE20210685A1 (es) 2018-07-03 2021-04-08 Gilead Sciences Inc Anticuerpos que se dirigen al gp120 de vih y metodos de uso
CA3103987C (en) 2018-07-06 2023-08-01 Gilead Sciences, Inc. Therapeutic heterocyclic compounds
KR102629921B1 (ko) 2018-07-06 2024-01-31 길리애드 사이언시즈, 인코포레이티드 치료 헤테로시클릭 화합물
CN120078775A (zh) 2018-07-16 2025-06-03 吉利德科学公司 用于治疗hiv的衣壳抑制剂
TWI766172B (zh) 2018-07-30 2022-06-01 美商基利科學股份有限公司 抗hiv化合物
CA3113011A1 (en) 2018-09-19 2020-03-26 Gilead Sciences, Inc. Integrase inhibitors for the prevention of hiv
EP3860717A1 (en) 2018-10-03 2021-08-11 Gilead Sciences, Inc. Imidozopyrimidine derivatives
MX2021005047A (es) 2018-10-31 2021-09-08 Gilead Sciences Inc Compuestos de 6-azabenzimidazol sustituidos como inhibidores de hpk1.
CN117105933A (zh) 2018-10-31 2023-11-24 吉利德科学公司 具有hpk1抑制活性的取代的6-氮杂苯并咪唑化合物
CA3118752A1 (en) * 2018-11-09 2020-05-14 Vivace Therapeutics, Inc. Bicyclic compounds
WO2020176505A1 (en) 2019-02-25 2020-09-03 Gilead Sciences, Inc. Protein kinase c agonists
WO2020176510A1 (en) 2019-02-25 2020-09-03 Gilead Sciences, Inc. Protein kinase c agonists
US11766447B2 (en) 2019-03-07 2023-09-26 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 3′3′-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator
AU2020231115B2 (en) 2019-03-07 2025-02-20 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 3'3'-cyclic dinucleotides and prodrugs thereof
DK3934757T3 (da) 2019-03-07 2023-04-17 Inst Of Organic Chemistry And Biochemistry Ascr V V I 2'3'-cykliske dinukleotider og prodrugs deraf
WO2020197991A1 (en) 2019-03-22 2020-10-01 Gilead Sciences, Inc. Bridged tricyclic carbamoylpyridone compounds and their pharmaceutical use
ES3014444T3 (en) 2019-04-16 2025-04-22 Vivace Therapeutics Inc Bicyclic compounds
US20200347036A1 (en) 2019-04-17 2020-11-05 Gilead Sciences, Inc. Solid forms of an hiv protease inhibitor
TW202104210A (zh) 2019-04-17 2021-02-01 美商基利科學股份有限公司 Hiv蛋白酶抑制劑
TW202212339A (zh) 2019-04-17 2022-04-01 美商基利科學股份有限公司 類鐸受體調節劑之固體形式
TWI751516B (zh) 2019-04-17 2022-01-01 美商基利科學股份有限公司 類鐸受體調節劑之固體形式
TW202231277A (zh) 2019-05-21 2022-08-16 美商基利科學股份有限公司 鑑別對使用gp120 v3聚醣導向之抗體的治療敏感之hiv病患的方法
TWI826690B (zh) 2019-05-23 2023-12-21 美商基利科學股份有限公司 經取代之烯吲哚酮化物及其用途
RU2717101C1 (ru) 2019-06-03 2020-03-18 Андрей Александрович Иващенко Анелированные 9-гидрокси-1,8-диоксо-1,3,4,8-тетрагидро-2Н-пиридо[1,2-a]пиразин-7-карбоксамиды - ингибиторы интегразы ВИЧ, способы их получения и применения
CA3140708A1 (en) 2019-06-18 2020-12-24 Helen Horton Combination of hepatitis b virus (hbv) vaccines and pyridopyrimidine derivatives
PE20220231A1 (es) 2019-06-25 2022-02-07 Gilead Sciences Inc Proteinas de fusion flt3l-fc y metodos de uso
EP3999107A1 (en) 2019-07-16 2022-05-25 Gilead Sciences, Inc. Hiv vaccines and methods of making and using
WO2021011891A1 (en) 2019-07-18 2021-01-21 Gilead Sciences, Inc. Long-acting formulations of tenofovir alafenamide
US20220296619A1 (en) 2019-08-19 2022-09-22 Gilead Sciences, Inc. Pharmaceutical formulations of tenofovir alafenamide
AU2020391466B2 (en) 2019-11-26 2024-05-23 Gilead Sciences, Inc. Capsid inhibitors for the prevention of HIV
MX2022007930A (es) 2019-12-24 2022-08-08 Carna Biosciences Inc Compuestos moduladores de diacilglicerol quinasa.
IL295677A (en) 2020-02-24 2022-10-01 Gilead Sciences Inc Tetracyclic compounds for treating hiv infection
AR121620A1 (es) 2020-03-20 2022-06-22 Gilead Sciences Inc Profármacos de nucleósidos 4’-c-sustituidos-2-halo-2’-deoxiadenosina y métodos de preparación y uso de los mismos
WO2021236944A1 (en) 2020-05-21 2021-11-25 Gilead Sciences, Inc. Pharmaceutical compositions comprising bictegravir
CA3181690A1 (en) 2020-06-25 2021-12-30 Chienhung CHOU Capsid inhibitors for the treatment of hiv
US12110305B2 (en) 2020-08-07 2024-10-08 Gilead Sciences, Inc. Prodrugs of phosphonamide nucleotide analogues and their pharmaceutical use
US12421235B2 (en) 2020-09-30 2025-09-23 Gilead Sciences, Inc. Bridged tricyclic carbamoylpyridone compounds and uses thereof
TWI815194B (zh) 2020-10-22 2023-09-11 美商基利科學股份有限公司 介白素2-Fc融合蛋白及使用方法
PT4244396T (pt) 2020-11-11 2025-10-20 Gilead Sciences Inc Métodos de identificação de doentes com hiv sensíveis à terapia com anticorpos dirigidos ao sítio de ligação cd4 da gp120
PT4196479T (pt) 2021-01-19 2024-01-03 Gilead Sciences Inc Compostos de piridotriazinas substituídos e suas utilizações
EP4284805A1 (en) 2021-02-01 2023-12-06 Celgene Corporation Mk2 inhibitors, the synthesis thereof, and intermediates thereto
US20220389394A1 (en) 2021-05-18 2022-12-08 Gilead Sciences, Inc. METHODS OF USING FLT3L-Fc FUSION PROTEINS
WO2022271684A1 (en) 2021-06-23 2022-12-29 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
KR20240005901A (ko) 2021-06-23 2024-01-12 길리애드 사이언시즈, 인코포레이티드 디아실글리세롤 키나제 조절 화합물
WO2022271659A1 (en) 2021-06-23 2022-12-29 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
JP7686086B2 (ja) 2021-06-23 2025-05-30 ギリアード サイエンシーズ， インコーポレイテッド ジアシルグリエルコール（ｄｉａｃｙｌｇｌｙｅｒｃｏｌ）キナーゼ調節化合物
PL4445900T3 (pl) 2021-12-03 2025-09-22 Gilead Sciences, Inc. Związki terapeutyczne przeciwko zakażeniu wirusem hiv
WO2023102523A1 (en) 2021-12-03 2023-06-08 Gilead Sciences, Inc. Therapeutic compounds for hiv virus infection
WO2023102529A1 (en) 2021-12-03 2023-06-08 Gilead Sciences, Inc. Therapeutic compounds for hiv virus infection
TWI856796B (zh) 2022-04-06 2024-09-21 美商基利科學股份有限公司 橋聯三環胺甲醯基吡啶酮化合物及其用途
TW202434566A (zh) 2022-07-01 2024-09-01 美商基利科學股份有限公司 可用於hiv病毒感染之疾病預防性或治療性治療的治療性化合物
CN119677546A (zh) 2022-07-12 2025-03-21 吉利德科学公司 Hiv免疫原性多肽和疫苗及其用途
CA3265134A1 (en) 2022-08-26 2024-02-29 Gilead Sciences Inc DOSING AND PLANNING REGIMEN FOR BROADLY NEUTRALIZING ANTIBODIES
EP4598934A1 (en) 2022-10-04 2025-08-13 Gilead Sciences, Inc. 4'-thionucleoside analogues and their pharmaceutical use
AU2024259111A1 (en) 2023-04-19 2025-10-16 Gilead Sciences, Inc. Dosing regimen of capsid inhibitor
US20250051375A1 (en) 2023-05-31 2025-02-13 Gilead Sciences, Inc. Anti-hiv compounds
TW202448483A (zh) 2023-05-31 2024-12-16 美商基利科學股份有限公司 用於ｈｉｖ之治療性化合物
US20250011352A1 (en) 2023-05-31 2025-01-09 Gilead Sciences, Inc. Solid forms
WO2025029247A1 (en) 2023-07-28 2025-02-06 Gilead Sciences, Inc. Weekly regimen of lenacapavir for the treatment and prevention of hiv
WO2025042394A1 (en) 2023-08-23 2025-02-27 Gilead Sciences, Inc. Dosing regimen of hiv capsid inhibitor
WO2025076542A1 (en) 2023-10-05 2025-04-10 Jones R Brad Atovaquone as an ros inducer for use in the elimination of hiv-infected t-cells
US20250120989A1 (en) 2023-10-11 2025-04-17 Gilead Sciences, Inc. Bridged tricyclic carbamoylpyridone compounds and uses thereof
US20250122219A1 (en) 2023-10-11 2025-04-17 Gilead Sciences, Inc. Bridged tricyclic carbamoylpyridone compounds and uses thereof
US20250127801A1 (en) 2023-10-11 2025-04-24 Gilead Sciences, Inc. Bridged tricyclic carbamoylpyridone compounds and uses thereof
WO2025137245A1 (en) 2023-12-22 2025-06-26 Gilead Sciences, Inc. Solid forms of hiv integrase inhibitors
WO2025184609A1 (en) 2024-03-01 2025-09-04 Gilead Sciences, Inc. Antiviral compounds
US20250296932A1 (en) 2024-03-01 2025-09-25 Gilead Sciences, Inc. Pharmaceutical compositions comprising hiv integrase inhibitors
US20250289822A1 (en) 2024-03-01 2025-09-18 Gilead Sciences, Inc. Solid forms of hiv integrase inhibitors
WO2025212814A1 (en) 2024-04-03 2025-10-09 Gilead Sciences, Inc. Anti-hiv compounds

Family Cites Families (86)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3895028A (en) 1972-09-12 1975-07-15 Tokyo Tanabe Co Alpha-(2-phenylbenzothiazol-5-yl)propionic acid
JPS4994667A (enExample) 1973-01-23 1974-09-09
FR2453163A1 (fr) 1979-04-03 1980-10-31 Rolland Sa A Derives de benzothiazole, leur procede de preparation et leurs applications en therapeutique
US4816570A (en) 1982-11-30 1989-03-28 The Board Of Regents Of The University Of Texas System Biologically reversible phosphate and phosphonate protective groups
GB8403739D0 (en) 1984-02-13 1984-03-14 Roussel Lab Ltd Chemical compounds
US4968788A (en) 1986-04-04 1990-11-06 Board Of Regents, The University Of Texas System Biologically reversible phosphate and phosphonate protective gruops
JPH03287558A (ja) 1990-04-05 1991-12-18 Teijin Ltd 酵素阻害剤
DE69115694T2 (de) 1990-06-13 1996-10-17 Arnold Newton Mass. Glazier Phosphorylierte prodrugs
DE10399025I2 (de) 1990-09-14 2007-11-08 Acad Of Science Czech Republic Wirkstoffvorläufer von Phosphonaten
MX9308016A (es) 1992-12-22 1994-08-31 Lilly Co Eli Compuestos inhibidores de la proteasa del virus de la inmunodeficiencia humana, procedimiento para su preparacion y formulacion farmaceutica que los contiene.
US5733906A (en) 1993-10-12 1998-03-31 Eli Lilly And Company Inhibitors of HIV Protease useful for the treatment of Aids
CA2159639A1 (en) 1993-04-02 1994-10-13 Vincent J. Miles Method for selective inactivation of viral replication
US5434188A (en) 1994-03-07 1995-07-18 Warner-Lambert Company 1-ether and 1-thioether-naphthalene-2-carboxamides as inhibitors of cell adhesion and as inhibitors of the activation of HIV
DE4428932A1 (de) 1994-08-16 1996-02-22 Hoechst Ag Substituierte-Chinolinderivate, Verfahren zu ihrer Herstellung und ihre Verwendung
EP0948327B1 (en) * 1996-12-23 2006-03-08 Merck & Co., Inc. Antidiabetic agents
FR2761687B1 (fr) * 1997-04-08 2000-09-15 Centre Nat Rech Scient Derives de quinoleines, possedant notamment des proprietes antivirales, leurs preparations et leurs applications biologiques
AU747500B2 (en) 1998-04-09 2002-05-16 Merck & Co., Inc. Oxidation process using periodic acid
WO2000063152A1 (en) 1999-02-22 2000-10-26 The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services Acetylated and related analogues of chicoric acid as hiv integrase inhibitors
US20020052323A1 (en) 2000-08-30 2002-05-02 Jinhai Wang Quinoline-(C=O)-(multiple amino acids)-leaving group compounds for pharmaceutical compositions and reagents
JP3836791B2 (ja) 2000-11-21 2006-10-25 サネシス ファーマシューティカルズ， インコーポレイテッド リガンドの迅速な同定のための拡張されたテザー化アプローチ
FR2819507B1 (fr) * 2001-01-17 2007-09-28 Inst Rech Developpement Ird Quinoleines substituees pour le traitement de co-infections a protozoaires et a retrovirus
FR2839646B1 (fr) 2002-05-17 2008-04-11 Bioalliance Pharma Utilisation de derives de quinoleine a effet anti-integrase et ses applications
BR0305717A (pt) 2002-08-02 2004-09-28 Tibotec Pharm Ltd Inibidores da protease do hiv 2-amino-benzotiazol sulfonamida de amplo espectro
AU2003257822A1 (en) * 2002-08-13 2004-04-30 Shionogi And Co., Ltd. Heterocyclic compound having hiv integrase inhibitory activity
EP2371955A1 (en) 2002-09-26 2011-10-05 K.U. Leuven Research & Development Integrase cofactor
AR042095A1 (es) 2002-11-20 2005-06-08 Japan Tobacco Inc Compuesto 4-oxoquinolina y aplicacion del mismo como inhibidor de integrasa de vih
UA80571C2 (en) 2002-11-22 2007-10-10 Lilly Co Eli Quinolinyl-pyrrolopyrazoles
US7893096B2 (en) 2003-03-28 2011-02-22 Novartis Vaccines And Diagnostics, Inc. Use of small molecule compounds for immunopotentiation
CA2567851A1 (en) 2004-05-21 2006-01-05 Merck & Co., Inc. Amino cyclopentyl heterocyclic and carbocyclic modulators of chemokine receptor activity
US7087610B2 (en) 2004-06-03 2006-08-08 Bristol-Myers Squibb Company Benzothiazole antiviral agents
EP1773750A1 (en) 2004-06-22 2007-04-18 Smithkline Beecham Corporation Chemical compounds
TWI306401B (en) 2004-08-13 2009-02-21 Nat Health Research Institutes Benzothiazolium compounds
US20060094755A1 (en) * 2004-10-28 2006-05-04 Bioflexis, Llc Novel quinoline-based metal chelators as antiviral agents
TWI370820B (en) 2005-04-27 2012-08-21 Takeda Pharmaceutical Fused heterocyclic compounds
WO2006124780A2 (en) 2005-05-12 2006-11-23 Kalypsys, Inc. Ih-benzo [d] imidazole compounds as inhibitors of b-raf kinase
US7473784B2 (en) 2005-08-01 2009-01-06 Bristol-Myers Squibb Company Benzothiazole and azabenzothiazole compounds useful as kinase inhibitors
US7939545B2 (en) * 2006-05-16 2011-05-10 Boehringer Ingelheim International Gmbh Inhibitors of human immunodeficiency virus replication
CA2651979A1 (en) * 2006-05-30 2007-12-06 Pfizer Products Inc. Triazolopyridazine derivatives
JO2841B1 (en) 2006-06-23 2014-09-15 تيبوتيك فارماسيوتيكالز ليمتد 2-(substituted-amino) -benzothiazole sulfonamide as protease inhibitors HIV (HIV)
US8435774B2 (en) 2006-06-28 2013-05-07 Qiagen Gmbh Enhancing reactivation of thermostable reversibly inactivated enzymes
WO2008053478A2 (en) 2006-10-30 2008-05-08 Yissum Research Development Company Of The Hebrew University Of Jerusalem Compositions and methods for inhibiting hiv-1 replication and integrase activity
CA2671478C (en) 2006-12-13 2015-02-17 F. Hoffmann-La Roche Ag Non-nucleoside reverse transcriptase inhibitors
RU2503679C2 (ru) 2007-11-15 2014-01-10 Джилид Сайенсиз, Инк. Ингибиторы репликации вируса иммунодефицита человека
US8377960B2 (en) * 2007-11-15 2013-02-19 Gilead Sciences, Inc. Inhibitors of human immunodeficiency virus replication
WO2009062285A1 (en) * 2007-11-16 2009-05-22 Boehringer Ingelheim International Gmbh Inhibitors of human immunodeficiency virus replication
CA2705338A1 (en) 2007-11-16 2009-05-22 Boehringer Ingelheim International Gmbh Inhibitors of human immunodeficiency virus replication
GB0801940D0 (en) 2008-02-01 2008-03-12 Univ Leuven Kath Inhibitors of lentiviral replication
JP2011511005A (ja) 2008-02-04 2011-04-07 オーエスアイ・フアーマスーテイカルズ・インコーポレーテツド ２−アミノピリジン系キナーゼ阻害薬
EP2362775B1 (en) 2008-11-20 2015-08-05 GlaxoSmithKline LLC Chemical compounds
GB0908394D0 (en) 2009-05-15 2009-06-24 Univ Leuven Kath Novel viral replication inhibitors
US8338441B2 (en) 2009-05-15 2012-12-25 Gilead Sciences, Inc. Inhibitors of human immunodeficiency virus replication
MX336687B (es) 2009-06-30 2016-01-28 Siga Technologies Inc Tratamiento y prevencion de infecciones del virus del dengue.
GB0913636D0 (en) 2009-08-05 2009-09-16 Univ Leuven Kath Novel viral replication inhibitors
US9095596B2 (en) 2009-10-15 2015-08-04 Southern Research Institute Treatment of neurodegenerative diseases, causation of memory enhancement, and assay for screening compounds for such
ES2475970T3 (es) 2009-12-23 2014-07-11 Katholieke Universiteit Leuven Novedosos compuestos antivirales
US20110223131A1 (en) 2010-02-24 2011-09-15 Gilead Sciences, Inc. Antiviral compounds
NZ603644A (en) 2010-05-24 2014-10-31 Univ Rochester Bicyclic heteroaryl kinase inhibitors and methods of use
WO2012003498A1 (en) 2010-07-02 2012-01-05 Gilead Sciences, Inc. 2 -quinolinyl- acetic acid derivatives as hiv antiviral compounds
MA34397B1 (fr) 2010-07-02 2013-07-03 Gilead Sciences Inc Dérivés d'acide napht-2-ylacétique dans le traitement du sida
US8633200B2 (en) 2010-09-08 2014-01-21 Bristol-Myers Squibb Company Inhibitors of human immunodeficiency virus replication
BR112013011991A2 (pt) 2010-11-15 2016-08-30 Viiv Healthcare Uk Ltd composto, composição farmacêutica, uso de um composto, método de tratamento, produto, e kit.
KR20140003438A (ko) 2010-11-15 2014-01-09 카톨리에케 유니버시테이트 루벤 항바이러스성 축합 헤테로사이클릭 화합물
AR084457A1 (es) 2010-12-22 2013-05-15 Lundbeck & Co As H Derivados de biciclo[3,2,1]octilamida
AU2012209373A1 (en) 2011-01-24 2013-04-11 Glaxosmithkline Llc Isoquinoline compounds and methods for treating HIV
AU2012240313A1 (en) 2011-04-04 2013-05-02 Gilead Sciences, Inc. Solid state forms of HIV inhibitor
TW201302760A (zh) 2011-04-04 2013-01-16 Gilead Sciences Inc 製備ｈｉｖ整合酶抑制劑之方法
EP2508511A1 (en) 2011-04-07 2012-10-10 Laboratoire Biodim Inhibitors of viral replication, their process of preparation and their therapeutical uses
EP2511273B8 (en) 2011-04-15 2019-06-26 Hivih Inhibitors of viral replication, their process of preparation and their therapeutical uses
WO2012145728A1 (en) 2011-04-21 2012-10-26 Gilead Sciences, Inc. Benzothiazole compounds and their pharmaceutical use
WO2013002357A1 (ja) 2011-06-30 2013-01-03 塩野義製薬株式会社 Ｈｉｖ複製阻害剤
US8791108B2 (en) 2011-08-18 2014-07-29 Bristol-Myers Squibb Company Inhibitors of human immunodeficiency virus replication
ES2632443T3 (es) 2011-09-22 2017-09-13 Viiv Healthcare Uk Limited Compuestos de pirrolopiridinona y procedimientos de tratamiento del VIH
WO2013058448A1 (ko) 2011-10-20 2013-04-25 한국해양연구원 내분비계 장애물질 노출에 대응하는 바다송사리 유전자 및 이를 이용한 수생태계 환경오염 진단 방법
JP6099149B2 (ja) 2011-10-25 2017-03-22 塩野義製薬株式会社 Ｈｉｖ複製阻害剤
WO2013103724A1 (en) 2012-01-04 2013-07-11 Gilead Sciences, Inc. 2- (tert - butoxy) -2- (7 -methylquinolin- 6 - yl) acetic acid derivatives for treating aids
WO2013103738A1 (en) 2012-01-04 2013-07-11 Gilead Sciences, Inc. Napthalene acetic acid derivatives against hiv infection
KR102438072B1 (ko) 2012-01-12 2022-08-31 예일 유니버시티 E3 유비퀴틴 리가아제에 의한 표적 단백질 및 다른 폴리펩티드의 증진된 분해를 위한 화합물 및 방법
US8629276B2 (en) 2012-02-15 2014-01-14 Bristol-Myers Squibb Company Inhibitors of human immunodeficiency virus replication
US9034882B2 (en) 2012-03-05 2015-05-19 Bristol-Myers Squibb Company Inhibitors of human immunodeficiency virus replication
US9006235B2 (en) 2012-03-06 2015-04-14 Bristol-Myers Squibb Company Inhibitors of human immunodeficiency virus replication
WO2013157622A1 (ja) 2012-04-19 2013-10-24 塩野義製薬株式会社 Ｈｉｖ複製阻害剤
EP3070081B1 (en) 2012-04-20 2018-02-28 Gilead Sciences, Inc. Benzothiazol-6-yl acetic acid derivatives and their use for treating an hiv infection
AU2013288369B2 (en) 2012-07-12 2018-03-29 Viiv Healthcare Uk Limited Compounds and methods for treating HIV
US8906929B2 (en) 2012-08-16 2014-12-09 Bristol-Myers Squibb Company Inhibitors of human immunodeficiency virus replication
WO2014055618A1 (en) 2012-10-03 2014-04-10 Gilead Sciences, Inc. Solid state forms of hiv inhibitor: hemi-succinate of (2s)-2-tert-butoxy-2-(4-(2,3-dihydropyrano[4,3,2-de]quinolin-7-yl)-2-methylquinolin-3-yl)acetic acid)
US20140094609A1 (en) 2012-10-03 2014-04-03 Gilead Sciences, Inc. Process for the preparation of an hiv integrase inhibitor

Also Published As

Publication number Publication date
CL2012003723A1 (es) 2014-04-11
JP2015180696A (ja) 2015-10-15
MA34400B1 (fr) 2013-07-03
CN103209963A (zh) 2013-07-17
PH12013500015A1 (en) 2013-02-18
CO6660514A2 (es) 2013-04-30
NZ604716A (en) 2014-12-24
JP2013533885A (ja) 2013-08-29
TW201215595A (en) 2012-04-16
ES2669793T3 (es) 2018-05-29
AR082080A1 (es) 2012-11-07
AU2011274323A1 (en) 2013-01-31
UY33479A (es) 2012-01-31
US20130210801A1 (en) 2013-08-15
US9296758B2 (en) 2016-03-29
EP2588455B1 (en) 2018-04-04
BR112012033689A2 (pt) 2019-09-24
JP5806735B2 (ja) 2015-11-10
KR20130124291A (ko) 2013-11-13
TWI458711B (zh) 2014-11-01
CA2802492A1 (en) 2012-01-05
CR20130043A (es) 2013-05-16
PE20130525A1 (es) 2013-05-05
ZA201209602B (en) 2015-06-24
SG186821A1 (en) 2013-02-28
EP2588455A1 (en) 2013-05-08
EA201291301A1 (ru) 2013-05-30
AU2011274323B2 (en) 2015-08-06
CA2802492C (en) 2018-10-16
WO2012003498A1 (en) 2012-01-05
PT2588455T (pt) 2018-06-29
ECSP13012418A (es) 2013-03-28
MX2012015293A (es) 2013-05-30

Similar Documents

Publication Publication Date Title
AP2013006707A0 (en) 2-Quinolinyl-acetic acid derivatives as HIV antiviral compounds
HRP20181384T1 (hr) Kondenzirani imidazolilimidazoli kao antivirusni spojevi
IL226004A0 (en) New antiviral compounds
IL226346A0 (en) Antiviral compounds
EP2580190A4 (en) NEW ANTIVIRAL COMPOUNDS
ZA201308086B (en) Derivatives of 1-anino-2-cyclopropylboronic acid
IL254176A0 (en) Improvements relating to antiviral preparations
EP2758419B8 (en) Novel betulinic acid derivatives with antiviral activity
ZA201402552B (en) Anti-viral azide-containing compounds
EP2585073A4 (en) ANTIVIRAL COMPOUNDS
EP2699241A4 (en) ANTIVIRAL COMPOUNDS
EP2691106A4 (en) ANTIVIRAL COMPOSITION
BR112013002089A2 (pt) compostos antivirais contendo azida
EP2782585A4 (en) ANTIVIRAL PREPARATIONS
ZA201306909B (en) Antiviral composition
GB201001204D0 (en) Novel antiviral compounds
HK1189883A (en) Novel antiviral compounds
ZA201402374B (en) Antiviral compounds
AU2011200745B2 (en) 4-hydroxybutyric acid analogs